Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 47 Melanoma 23 Neoplasm Metastasis 19 Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 17 Lung Neoplasms 13 Skin Neoplasms 12 Head and Neck Neoplasms 10 Recurrence 9 Carcinoma, Renal Cell 9 Prostatic Neoplasms 8 Ovarian Neoplasms 8 Colorectal Neoplasms 8 Carcinoma, Squamous Cell 8 Breast Neoplasms 8 Urinary Bladder Neoplasms 7 Carcinoma, Merkel Cell 7 Triple Negative Breast Neoplasms 6 Colonic Neoplasms 6 Carcinoma, Basal Cell 6 Carcinoma 6 Adenocarcinoma 6 Uterine Cervical Neoplasms 5 Pancreatic Neoplasms 5 Stomach Neoplasms 4 Sarcoma 4 Multiple Myeloma 4 Mouth Neoplasms 4 Glioblastoma 4 Fallopian Tube Neoplasms 4

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 10 Drug Therapy 9 aflutinib 8 Gefitinib 7 Radiotherapy 6 Docetaxel 6 Cisplatin 6 anlotinib 5 Radiosurgery 5 Paclitaxel 5 pembrolizumab 4 Vinorelbine 4 Gemcitabine 4 tislelizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × cemiplimab × Clear all

NCT06865339 2026-04-13

TRIPL

Montefiore Medical Center

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡